Skip to content

Meditative Neurofeedback for Depression

Meditative Neurofeedback for Depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06675240
Acronym
MediNF
Enrollment
27
Registered
2024-11-05
Start date
2024-11-15
Completion date
2027-11-15
Last updated
2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression Disorders, Depression - Major Depressive Disorder

Keywords

meditation, neurofeedback, rumination, EEG, anxiety, depression

Brief summary

The goal of this study is to test a meditative neurofeedback intervention for depressed mood.

Detailed description

The goal of this study is to test whether a 5-session meditative neurofeedback intervention significantly alleviates depressive symptoms as well as improves secondary outcomes of rumination and mindfulness.

Interventions

BEHAVIORALMediNF

Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.

Sponsors

University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* moderate depression per PHQ9 symptom ratings

Exclusion criteria

* active substance abuse/dependence * psychotic disorders * bipolar disorder * displaying acutely suicidal behaviors

Design outcomes

Primary

MeasureTime frameDescription
PHQ98 weeksDepression Symptoms on the Patient Health Questionnaire 9-item (PHQ9) scale, min 0 max 27 with lower scores representing better outcome

Secondary

MeasureTime frameDescription
MAAS8 weeksMindfulness on the Mindful Attention Awareness Scale (MAAS), min 6 max 84 with higher scores representing better outcome
RRQ8 weeksRumination on the Ruminative Response Questionnaire (RRQ) scale, min 22 max 88 with lower scores representing better outcome
GAD78 weeksAnxiety symptoms on the Generalized Anxiety Disorder 7-item (GAD7) scale, min 0 max 21 with lower scores representing better outcome

Countries

United States

Contacts

CONTACTJyoti Mishra, PhD
braine@ucsd.edu619-940-4230

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026